1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Sinovac Biotech Ltd.

Sinovac Biotech Ltd.

SVA
Sinovac Biotech Ltd.US flagNASDAQ Global Select
6.47
USD
- -
- -
464.94MMarket Cap

Total Valuation

Sinovac Biotech Ltd. carries a market capitalization of 464.94M, placing it among publicly traded companies globally. Its enterprise value stands at -666.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap464.94M
Enterprise Value-666.20M

Share Statistics

Sinovac Biotech Ltd. currently has 99.29M shares outstanding.

Shares Outstanding99.29M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Enterprise Valuation

On an enterprise value basis, Sinovac Biotech Ltd. trades at an EV/EBITDA multiple of 24.93 and an EV/FCF ratio of 18.10. The EV/Sales ratio of 5.28 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 27.99 provides insight into valuation relative to core operating earnings.

EV / Sales5.28
EV / EBITDA24.93
EV / EBIT27.99
EV / FCF18.10

Financial Position

Sinovac Biotech Ltd. maintains a current ratio of 2.30, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.18, indicating elevated leverage, while an interest coverage ratio of 151.30 demonstrates strong ability to service its debt obligations.

Current Ratio2.30
Quick Ratio2.10
Debt / Equity12.18
Debt / EBITDA0.62
Interest Coverage151.30

Financial Efficiency

Sinovac Biotech Ltd. posts a return on equity of 103.75 and a return on invested capital of 22.18.

Return on Equity (ROE)103.75
Return on Assets (ROA)9.38
Return on Invested Capital (ROIC)22.18
Return on Capital Employed (ROCE)9.32
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.01

Taxes

Over the trailing twelve months, Sinovac Biotech Ltd. has paid 31.44M in income taxes, reflecting an effective tax rate of 14.51.

Income Tax31.44M
Effective Tax Rate14.51

Stock Price Statistics

Sinovac Biotech Ltd.'s stock has gained approximately 0% over the past 52 weeks. The 50-day moving average sits at 6.47, while the 200-day moving average is 6.47.

Beta (5Y)N/A
52-Week Price Change0%
50-Day Moving Average6.47
200-Day Moving Average6.47
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Sinovac Biotech Ltd. generated 510.62M in revenue and converted that into 110.37M in net income, yielding earnings per share of 1.74. EBITDA reached 219.84M, while operating income came in at 215.81M.

Revenue510.62M
Gross Profit443.44M
Operating Income215.81M
Pretax Income216.62M
Net Income110.37M
EBITDA219.84M
EBIT215.81M
Earnings Per Share (EPS)1.74

Balance Sheet

Sinovac Biotech Ltd. holds 1.18B in cash and equivalents against 136.39M in total debt, resulting in a net debt position of -993.63M. Total book value stands at 144.34M, with working capital of 880.68M providing operational flexibility.

Cash & Cash Equivalents1.18B
Total Debt136.39M
Net Debt-993.63M
Equity (Book Value)144.34M
Book Value Per Share1.46
Working Capital880.68M

Cash Flow

Sinovac Biotech Ltd. produced 479.31M in operating cash flow over the past twelve months. After subtracting -127.49M in capital expenditures, free cash flow totaled 351.82M - equivalent to 3.56 per share.

Operating Cash Flow479.31M
Capital Expenditures-127.49M
Free Cash Flow351.82M
FCF Per Share3.56

Margins

Sinovac Biotech Ltd. operates with a gross margin of 86.84, reflecting its pricing power and cost economics. The operating margin of 42.26 and net profit margin of 21.61 provide insight into operational efficiency.

Gross Margin86.84
Operating Margin42.26
Pretax Margin42.42
Profit Margin21.61
EBITDA Margin43.05

Dividends & Yields

The company's payout ratio of -2.37 indicates the proportion of earnings distributed to shareholders.

Dividend Per ShareN/A
Dividend YieldN/A
Payout Ratio-2.37
Shareholder YieldN/A
FCF YieldN/A

Scores

Sinovac Biotech Ltd. posts an Altman Z-Score of 1.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.31